Estrogen and progestin receptors (ER,PgR
. Although receptors for E (ER) and progestins (PgR) were discovered in the brain of female rats in the 1960s and 1970s, the more recent discovery of different subtypes and/or isoforms of these receptors has added another layer of complexity to the study of steroid signaling in the brain. In particular, the recently discovered second ER, ER␤ (2) (3) (4) , is expressed in the brain of a number of species (5, 6 ).
ER␤ shares a high level of sequence identity with ER␣ in some receptor domains, and both receptors bind to estradiol (E2) with similar affinity (7) . However, ER␤ and ER␣ can exhibit different transcriptional activities in cotransfection experiments depending on the ligands and promoters tested (8, 9) . Furthermore, ER␤ and ER␣ have the ability to homodimerize and heterodimerize and display different transcriptional activities dependent on the particular dimer that is formed (10, 11) . Thus, cellular responses to estrogenic ligands may depend in part on the presence and ratio of the ER subtypes. Therefore, to study E signaling in the brain, it is important to determine the extent of cellular coexpression of ER␤ and ER␣ in specific neuroanatomical areas.
Recent studies have demonstrated that progesterone can alter the expression of ER␤ mRNA in human breast tumors (12) and monkey corpus luteum (13) . Additionally, one study showed that E2 acts through ER␤ to induce PgR expression in a colon cancer cell line (14) . In the brain virtually all cells in which E2 induces PgR expression contain ER␣ (15) . However, E2 also induces some PgR expression in ER␣ knockout mice (ER␣KO). This response could be due to the presence of residual ER␣ variants (16, 17) . Alternatively, ER␤ may mediate PgR induction upon E2 treatment in the ER␣KO (17) . To examine whether the presence of ER␤ alters the expression of PgR in female rat brain, it is essential to first determine whether ER␤ and PgR are present within the same cells.
ER␤ mRNA has been detected in the brain by both RT-PCR and in situ hybridization (5, 7) . Substantial quantities of ER␤ mRNA exist in hypothalamic and limbic regions of the brain, which are known to contain high levels of ER␣ and PgR. ER␤ mRNA has also been detected in other regions of the brain [supraoptic nucleus and paraventricular nucleus (PVN)] known to express little or no ER␣ or PgR (5) . Recently, Shughrue et al. (18) also observed the presence of ER␣-immunoreactivity (ER␣-ir) in ER␤ mRNA-containing neurons of limbic and hypothalamic regions of the female rat brain, suggesting that in vivo, ER␣ and ER␤ proteins may be expressed within the same cells. ER␤ protein has also been detected in rat brain by use of immunocytochemistry (19) . In this study, which used an affinity-purified polyclonal antibody raised against the C-terminus of rat ER␤, ER␤ protein was seen in a more limited number of cells and in fewer regions than ER␤ mRNA by in situ hybridization.
In the present study we determined the extent of cellular coexpression of ER␤-ir with ER␣-ir as well as ER␤-ir with PgR-ir in different brain regions, using a newly developed monoclonal antibody raised against a peptide from the Nterminal region of ER␤. The resulting distribution of ER␤-ir cells closely matched the distribution of cells containing moderate to high levels of ER␤ mRNA in female rat brain (5) . A double label immunofluorescence technique was used to Abbreviations: BNSTpr, Bed nucleus of the stria terminalis; E, estrogen; E2, estradiol; EB, E2 benzoate; ER␤-ir, ER␤-immunoreactivity; ER␣KO, ER␣ knockout mice; hER, human ER; MEApd, medial amygdala; OVX, ovariectomized; PgR, progestin receptor; PVN, paraventricular nucleus; PvPO, periventricular preoptic area; TBS, Tris-buffered saline.
determine whether ER␤-ir was present in ER␣-ir-or PgRir-containing neurons in forebrain regions of ovariectomized female rats. Moreover, we tested the hypothesis that E2 treatment influenced the distribution and the ratio of coexpression of these receptors.
Materials and Methods Animals
Female Sprague Dawley rats (175-200 g; Charles River Laboratories, Inc. Breeding Laboratories, Inc., Wilmington, MA) were group-housed for 1 wk in a 14-h light, 10-h dark cycle, with food and water available ad libitum. Procedures were approved by the institutional animal care and use committee of the University of Massachusetts (Amherst, MA). All rats were then ovariectomized (OVX) after ip injections of a cocktail of xylazine (5 mg/kg), ketamine (26 mg/kg), and acetopromazine (0.9 mg/kg). One week after surgeries, levels of circulating E2 are extremely low, and a bolus injection of 10 g E2 benzoate (EB) restores them within 24 h. Thus, 1 wk later, the experimental group of females was injected sc with either 10 g EB (n ϭ 5) or sesame oil vehicle (0.1 ml; n ϭ 5), and animals were killed 48 h later.
Immunoblotting
Protein extracts were from Sf21 insect cells infected without or with human (h) ER␤ (1-485) or wild-type hER␣ recombinant virus. Cells were harvested, washed, and lysed in ice cold buffer containing 0.4 m KCl, 10 mm Tris (pH 7.5), 0.5 mm phenylmethylsulfonylfluoride, 1 g/ml aprotinin, and 1 mm dithiothreitol. Soluble protein extracts were obtained by centrifugation at 100,000 ϫ g for 45 min at 4 C. Protein concentration was determined, and extracts were added to SDS-PAGE buffer, subjected to SDS-PAGE, and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc., Richmond, CA). Membranes were blocked in 5% Carnation instant nonfat dry milk in Tris-buffered saline (TBS; Bio-Rad Laboratories, Inc.) for 15 min. Primary hER␤ antibody (1 g/ml) was incubated with membranes overnight at room temperature in 0.5% milk in TBS/0.1% Tween-20. Goat antimouse secondary antibodies conjugated to alkaline phosphatase (Bio-Rad Laboratories, Inc.) were incubated with membranes for 2 h at room temperature in 0.5% milk/TBS/ 0.1% Tween-20. Washes and development of color were performed according to the Bio-Rad Laboratories, Inc., protocol.
Characterization of ER␤ and ER␣ antibodies: ligand-bound vs. unbound receptors
To determine whether variations in ER␤ or ER␣ immunostaining after E2 treatment may be attributable to differential recognition of ligandbound vs. unbound ERs by the respective antibodies, OVX female rats were injected sc with either 50 g 17␤-E2 dissolved in 0.1 ml vehicle (n ϭ 5) or the 50% ethanol-water vehicle (n ϭ 5), and they were perfused 20 min later. This treatment with a large amount of free E2 for a short period of time is believed to induce maximal ligand occupancy of ER␣ without resulting in down-regulation of the receptor protein (20) .
Control for ER down-regulation
To determine whether recognition of the antibody for the receptor is influenced by binding of EB at the same concentration as that used in the 48-h experiment and to determine whether any variations in ER␣ or ER␤ immunostaining at 48 h could be due to ER down-regulation, a second group of female rats was injected sc with the same dose of EB as the experimental group (10 g; n ϭ 4) or oil vehicle (0.1 ml; n ϭ 4), but they were perfused 2 h later, instead of 48 h later. This treatment is expected to result in higher levels of circulating E2 (21) and occupation of ERs (22) than in the 48 h experimental group, but considerably less than in the group receiving 50 g free E2 20 min before perfusion.
Perfusions
All animals received a lethal dose of sodium pentobarbital (89 mg/ kg), and they were perfused with 0.9% physiological saline (25 ml) for 1 min followed by 4% paraformaldehyde (25 ml/min) for 10 min. After the brains were removed from the cranium, they were placed into 0.1 m sodium phosphate buffer (pH 7.2) containing 20% sucrose for 48 h. Thirty-five-micron sections from the preoptic area to the midbrain region were cut on a freezing microtome, and the sections were placed into a cryoprotectant solution.
Double label immunofluorescence for ER␤-ir with either ER␣-ir or PgR-ir
For all animals, two sets of sections were removed from cryoprotectant and rinsed three times for 5 min each time in 0.05 m TBS, pH 7.6. Sections were placed into a solution containing 1% H 2 O 2 , 20% normal goat serum, and 1% BSA for 20 min. Sections were then incubated for 2 d at 4 C in a solution containing the mouse monoclonal hER␤ antibody (hER␤NT-221.3, Ligand Pharmaceuticals, Inc., San Diego, CA; 1 g/ml) raised against a synthetic peptide corresponding to the 14-amino acid N-terminal sequence of hER␤ (1-485 form) and either the rabbit polyclonal rat ER␣ antibody (C1355; gift from M. Shupnik, University of Virginia, Charlottesville, CA; 1:30,000) raised against the last 14-amino acid C-terminal sequence of rat ER␣ or the rabbit polyclonal human PgR antibody (DAKO Corp., Carpinteria, CA; 1:500) raised against a synthetic peptide corresponding to the DNA-binding domain of human PgR (PgR-A and PgR-B forms; 533-547), in a buffer containing TBS, 0.1% gelatin, 0.02% sodium azide, 0.5% Triton X-100, and 1% normal goat serum (TBS-gel). After three washes in TBS-gel buffer, the sections were incubated in a solution containing the cyanine goat antimouse (7 g/ml, to reveal ER␤-ir) and the fluorescein goat antirabbit (10 g/ml, to reveal ER␣-ir or PgR-ir) secondary antisera for 90 min at room temperature. The sections were then rinsed three times for 5 min each time in TBS, mounted onto slides, air-dried, and coverslipped with Vectashield mounting medium (Vector Laboratories, Inc., Burlingame, CA).
Immunocytochemistry controls
ER␤-ir preadsorption. To determine the specificity of the anti-ER␤ antibody immunostaining for ER␤, the anti-ER␤ antibody was preadsorbed at 4 C overnight with a 100-fold molar excess of its corresponding synthetic peptide before use in the immunostaining assays and was used to immunostain brain sections.
PgR-ir preadsorption.
To determine the specificity of the PgR immunostaining, the rabbit anti-PgR antibody was preadsorbed at 4 C overnight with a 100-fold molar excess of a mix of human PgR-A and PgR-B recombinant proteins (Tissue Culture Core Facility of the University of the Colorado Cancer Center) before use in immunostaining.
Double label immunofluorescent controls.
To control for nonspecific immunofluorescent staining, cross-immunoreactivity, and "bleedthrough" of the fluorochromes, sections were also incubated either in solutions in which the primary antibodies were omitted and the secondary antibodies were present or in solutions in which only one primary antibody was present and both secondary antibodies were present. No nonspecific immunofluorescent staining, cross-immunostaining, or bleed-through was observed (data not shown).
Data analysis
Quantification of double labeled immunofluorescent cells. Quantifications were performed on one matched section per brain region for each rat. Using the NIH Image computer analysis system (developed at the NIH and available at http://rsb.info.nih.gov/nih-image/), digitized pictures of the same microscopic field were captured with two different bandpass filters, specific for cyanine and fluorescein. The images were superimposed, and the numbers of single or double labeled cells were counted by eye in the brain region chosen. Because the main point of the present study was to report the level of colocalization of ER␤ with either ER␣ or PgR, the regions examined were selected based upon the presence of ER␤-ir cells, that is, in the principal nucleus of the bed nucleus of the stria terminalis (BNSTpr), the periventricular zone of the preoptic area (PvPO), the posterodorsal nucleus of the medial amygdala (MEApd), and PVN. The quantification for all groups was performed with a ϫ10 objective for each brain region (BNSTpr, 340 ϫ 300 m; PvPO, 580 ϫ 120 m; MEApd, 870 ϫ 240 m; PVN, 390 ϫ 480 m), except for the 2 h control groups, in which the quantification was performed with a ϫ20 objective (BNSTpr, 180 ϫ 160 m; PvPO, 420 ϫ 90 m; MEApd, 370 ϫ 160 m). In all microscopic fields observed, only cells that were clearly distinguishable were counted.
Variation in PgR immunofluorescent intensity in cells of oil-and EB-treated females.
Many studies have shown that variations in immunostaining intensity can be measured by variations in OD (mean pixel densities) (23) (24) (25) . Using inverted digitized pictures for PgR-ir, the mean pixel density of PgR-ir was measured in the PvPO, BNSTpr, MEApd, and PVN in oil-and EB-treated females, as described in detail previously (25) . In brief, the gain and black levels of the camera were set so that the gray level ranged from 0 to 255 pixel density for PgR immunoreactivity (0 being white and 255 being black). The density threshold was set to determine the contribution of the background immunoreactivity and to exclude it from the contribution of the foreground immunoreactivity. The OD of PgR-ir (i.e. the intensity of PgR immunofluorescence) was determined for each area and was represented by the average and sem of the pixel densities of the sections analyzed.
Variation in PgR immunofluorescent intensity in cells coexpressing ER␤-ir.
PgR-ir was apparent in many cells with or without EB treatment. However, the OD of PgR-ir in EB-treated females was considerably brighter (see above, Table 3 ). Therefore, to determine whether cells in which EB treatment increased PgR expression contained ER␤-ir, the darkly immunostained PgR neurons were counted in EB-treated females using a method similar to that described above. The density threshold was set to eliminate E2-independent PgR immunoreactivity in oil-treated females, and was used to measure foreground PgR immunoreactivity in EB-treated females. Processed images were superimposed on corresponding digitized pictures containing ER␤-ir, and the darkly immunostained PgR neurons coexpressing ER␤-ir were counted by eye in the PvPO, BNSTpr, and MEApd.
Statistical analysis. t tests with P Ͻ 0.05 were used to determine statistical difference in the mean number of labeled cells per brain regions and in the mean percent colocalization of steroid receptors in labeled cells per brain regions.
Results

Specificity of ER␤ antibody
Immunoblotting was used to test the specificity of the ER␤ antibody used in the immunostaining studies. An immunoreactive band of the predicted molecular mass of ER␤ (ϳ55 kDa) was observed on blots probed with the ER␤ antibody in lanes containing protein extract from insect cells infected with hER␤ recombinant virus, but not in lanes containing extracts from mock-or hER␣-infected cells (Fig. 1A) . Therefore, this antipeptide ER␤ monoclonal antibody reacts with ER␤, but not with ER␣, on a Western blot. Additionally, this antibody reacted with ligand-occupied ER␤, but not with holo-ER␣, as assessed by ligand binding immunoprecipitation of the recombinant proteins (data not shown). 
Characterization of ER␤ and ER␣ antibodies: ligand-bound vs. unbound receptors
As some steroid receptors antibodies are preferential in their binding to either the unoccupied (20) 
Neuronal distribution of ER␣-ir, ER␤-ir, and PgR-ir, and their regulation by EB treatment
The pattern of distribution of ER␣-ir in oil-or EB-treated female brains was consistent with previous reports (27) (28) (29) . ER␣-ir was present in nuclei of neurons of the preoptic area; the PvPO; the principal and medial nuclei of the BNST; the anterior, lateral and ventromedial hypothalamus; the parvocellular part of the PVN; the central, medial, and cortical amygdala; the arcuate nucleus; the piriform cortex; and, to a lesser extent, the hippocampus. The number of ER␣-ir neurons in the MEApd and PVN significantly decreased 48 h after EB treatment (P Ͻ 0.05; Table 1 ). The number of ER␣-ir cells did not vary in any brain region 2 h after treatment with 10 g EB vs. treatment with vehicle (oil vs. EB: in PvPO, 106.6 Ϯ 10.8 vs. 128.3 Ϯ 5.2; in BNSTpr, 208 Ϯ 7.9 vs. 181.4 Ϯ 40; in MEApd, 185.6 Ϯ 23 vs. 164 Ϯ 24.6), consistent with the finding that occupancy of ER␣ by E2 does not change the interaction of the ER␣ antibody, C1355, with ER␣. Therefore, the decrease in ER␣-ir cells observed at 48 h is probably due to down-regulation of ER␣ by E2.
The distribution of ER␤-ir cells was consistent with the expression patterns reported for ER␤ mRNA (5) and protein (19) . The hER␤ antibody used in this study specifically recognized recombinant ER␤ protein by immunoblotting (Fig.  1A) , and the immunostaining with this antibody was completely blocked by preadsorption of the antibody with the peptide that it was generated against (Fig. 1B) . In the forebrain, ER␤-ir was found in nuclei of cells in the PvPO, the dorsal and ventral BNSTpr, the dorsal and magnocellular part of the PVN, the anterior and caudal supraoptic nucleus, and the anterior and posterodorsal MEA (Fig. 2) . 20) . This suggests that the dose of EB (10 g) used in the experiment did not interfere with antibody binding to the receptor, even though a much larger dose of free E2 (50 g) interfered with immunostaining. Therefore, the decrease in ER␤-ir seen at 48 h represents down-regulation of ER␤-ir by E2.
The distribution of PgR-ir in the brain of both oil-and EB-treated female rats was more extensive than previously reported (25, 30 -32) , because of greater sensitivity of the immunostaining technique used here. No immunostaining was observed with PgR-preadsorbed PgR antibodies (data not shown). Many PgR-ir cells were detected in the preoptic area, BNST, the lateral and ventromedial hypothalamus, the arcuate nucleus, and, to a lesser extent, the parvocellular part of the PVN. PgR-ir was also observed in the hippocampus, the piriform cortex, various amygdala nuclei, the magnocellular part of the PVN, and layers III-VI of the cerebral cortex (data not shown). The number of PgR-ir neurons in the PvPO, the BNSTpr, the MEApd, and the PVN did not differ between oil-and EB-treated females (Table 2) . However, E2 treatment resulted in a significant increase (P Ͻ 0.05) in staining intensity (i.e. pixel density) of PgR-ir in the PvPO, BNSTpr, and MEApd of EB-treated females (Table 3) , consistent with previous findings that there is E2-independent PgR expression throughout the brain, and that E2 can also increase PgR levels.
Coexpression of ER␣-ir and ER␤-ir
Colocalization of ER␣-ir and ER␤-ir was observed in cells of the PvPO, the BNSTpr, and the MEApd (Table 1 and Fig.  3 ). The number of neurons expressing both ER␣-ir and ER␤-ir decreased significantly after EB treatment in the PvPO, BNSTpr, and MEApd (Table 1 ). The percentage of ER␣-ir neurons containing ER␤-ir in the PvPO and MEApd decreased significantly in the EB-treated group compared with the oiltreated group (P Ͻ 0.05; Fig. 4A) . Conversely, the percentage of ER␤-ir neurons containing ER␣-ir in the MEApd decreased significantly in the EB-treated group compared with the oil-treated group (P Ͻ 0.05; Figs. 4B). In the PVN, because ER␣-ir and ER␤-ir were in anatomically distant sites, very The numbers (mean Ϯ SEM) of ER␣-ir-, ER␤-ir-, and ER␣-ER␤-ircontaining neurons (cells per unit area; see Materials and Methods for area of each brain region) in the BNSTpr, PvPO, MEApd, and PVN of OVX rats treated for 48 h with oil (n ϭ 5) or EB (n ϭ 5) were counted as described in Materials and Methods.
a Significantly different from oil group (by t test, P Ͻ 0.05).
little colocalization of ER␣-ir and ER␤-ir was observed (Table  1 and Fig. 4, A and B) .
Coexpression of PgR-ir and ER␤-ir
Coexpression of PgR-and ER␤-ir was observed in cells of the PvPO, the BNSTpr, the MEApd, and the PVN ( Table 2 ). The number of neurons coexpressing both PgR-ir and ER␤-ir in all regions observed did not differ between groups ( Table  2 ). The percentage of PgR-ir neurons containing ER␤-ir in the PvPO decreased significantly in the EB-treated group compared with the oil-treated group (P Ͻ 0.05, Fig. 5A ). In all regions observed, there was no difference in the percentage of ER␤-ir neurons containing PgR-ir between groups (Fig. 5B) .
As in this experiment the PgR immunocytochemical pro- cedure used was more sensitive than in previous work, ERindependent PgR were also detected. To focus only on the E2-induced PgR expression, we adjusted our criterion of imaging PgR to eliminate ER-independent PgR-ir (see Materials and Methods). Upon counting only darkly immunostained PgR cells in the EB-treated group by selecting an upper threshold for pixel density as a mean of selecting only E2-induced PgR-ir cells, it was observed that about 35%, 28%, and 25% of PgR-ir neurons coexpressed ER␤-ir in the PvPO, the BNSTpr, and the MEApd, respectively (Fig. 6) .
Discussion
In the forebrain of female rats, ER␤-ir was coexpressed in ER␣-ir-and PgR-ir-containing neurons. Furthermore, E2 treatment modulated the expression of ER␤, ER␣, and PgR in a brain region-specific manner. This caused a change in the ratio of cells coexpressing both ER subtypes or ER␤ and PgR in specific brain areas. Also as expected, E2 treatment induced the expression of PgR in hypothalamic and limbic regions, which occurred in part in ER␤-ir-containing neurons.
The hER␤ antibody used in the present study appears to be very specific for ER␤ as assessed by immunoblotting and immunoprecipitation assays. The antibody reacted with ER␤, but not ER␣, PgR, or AR, by Western blot (Fig. 1A and data not shown) and by the elimination of immunostaining after antibody preadsorption with its specific peptide (Fig.  1B) . Although the antibody recognized the ligand-bound ER␤ by in vitro immunoprecipitation assays using recombinant proteins (data not shown), we found that sc treatment of ovariectomized female rats with a large amount of free E2 (50 g) eliminated ER␤ immunostaining in all brain regions.
This suggests that in brain tissue, this antibody does not react with ligand-bound ER␤. Discrepancies between in vitro and in vivo characteristics of antibodies have previously been reported, such as for the specific ER␣ antibody, H222 (20) . Although antibodies raised against the N-terminus of ER␣ were not reported to show differential interactions with ER␣ (20) , this may not be the case for the ER␤ antibody used in these studies. Blocking of the ER␤ antibody epitope by ligand binding may occur in vivo through conformational changes in ER␤ upon binding of ligand, by dimerization of the receptor with ER␣ or ER␤, or by interaction of ER␤ with other accessory proteins, such as cofactors.
The distribution of ER␤-ir (Fig. 2) as assessed with the N-terminus hER␤ monoclonal antibody was different from that in previous studies in which a polyclonal C-terminal rat ER␤ antibody was used (19, 33) . Using the C-terminal ER␤ antibody, fiber and cytoplasmic stainings were observed in the lateral septum and the hippocampus (19), which were not observed using the N-terminus ER␤ antibody. In contrast to the C-terminal antibody, which labeled cells in the lateral septum, the medial BNST, the PVN, the supraoptic nucleus, the anterior MEA, and the hippocampus (19) , the N-terminal antibody labeled numerous cells within the PvPO, the BNSTpr, the PVN, the supraoptic nucleus, and the MEApd, where the highest density of ER␤ mRNA-containing cells and the highest level of ER␤ mRNA have been reported (5) . This suggests that the human N-terminus ER␤ antibody used in the present study may specifically recognize cells containing moderate to high levels of ER␤. Thus, the extent of colocalization of ER␤ with ER␣ or PgR and the changes in the ratio of steroid-containing cells after hormonal treatment reported here may be underestimated. These should, of course, be taken as relative indexes of colocalization and not as absolute numbers. It is also possible that ER␤ mRNA is expressed at a higher level than ER␤ protein. Differential protein expression of ER␤ variants that have been reported in the brain (34) could also be an explanation for the differences in ER␤ distribution observed between in situ hybridization and immunocytochemical approaches.
Little work has been reported on the hormonal regulation of ER␤ in the brain. Previous studies reported that E2 treatment caused down-regulation of ER␤ mRNA expression in the PVN (35) and the MEA (36). Although we did not observe a decrease in the number of ER␤-ir cells in the PVN or the MEApd 48 h after EB injection, the number of ER␤-ir cells decreased in the PvPO and the BNSTpr. This decrease is probably due to down-regulation of ER␤ in specific brain regions. Although an injection of 50 g free E2 20 min before perfusion interfered with ER␤ antibody binding to ER␤, an injection of 10 g E2 benzoate 2 h before perfusion resulted in apparent levels of ER␤-ir not different from those observed The numbers (mean Ϯ SEM) of PgR-ir-, ER␤-ir-, and PgR-ER␤-ircontaining neurons (cells per unit area; see Materials and Methods for area of each brain region) in the BNSTpr, PvPO, MEApd, and PVN of OVX rats treated with oil (n ϭ 5) or EB (n ϭ 5) were counted as described in Materials and Methods.
a Significantly different from oil group (by t test, P Ͻ 0.05). Pixel density per area (mean Ϯ SEM) for PgR-ir labeled cells in the BNSTpr, PvPO, MEApd, and PVN of oil-(n ϭ 5) or EB-treated OVX female rats (n ϭ 5).
after vehicle treatment. This suggests that even though ER␤ immunostaining can be influenced by occupation of the receptor with a saturating dose of free E2 (50 g), exposure to a low level of circulating E2 (10 g EB) does not interfere with the ER␤ immunostaining. Thus, decreases in ER␤ immunostaining observed after EB injection are probably due to down-regulation of ER␤. Although this issue needs to be further examined with molecular approaches, the present results are consistent with reports of down-regulation of ER␤ mRNA in the brain (35, 36) and other tissues (37) after E2 treatment. Therefore, these findings suggest that ER␤ protein expression may be differentially regulated by E2 in various regions of the brain. Our observations on the presence of ER␣-ir in hypothalamic and limbic regions, including the PvPO, the BNSTpr, the parvocellular part of the PVN, and the MEApd, agree with previous reports using various ER␣ antibodies (27) (28) (29) . E2 treatment significantly decreased the number of ER␣-ir neurons in the MEApd and the PVN. This decrease is also probably due to a brain region-specific down-regulation of ER␣, as ligand binding did not influence ER␣-ir staining (with the C1355 antibody used in this study) in any brain region. Moreover, these findings agree with previous reports of down-regulation of ER␣ or ER␣ mRNA in the brain after E2 administration (38, 39) .
In vitro studies suggest that ER␤ and ER␣ may het- erodimerize (10) . For this heterodimerization to occur in the brain, both ER␣ and ER␤ must be expressed in the same neurons. Colocalization of ER␣-ir and ER␤-ir was observed in neurons of the PvPO, the BNSTpr, the MEApd, as well as the PVN. Depending on the region and the hormonal treatment, this represented less than 40% of the ER␣-containing cell population, but this represented over 60% of the ER␤-ir neurons, except in the PVN where very little colocalization was observed. Shughrue et al. (18) previously reported a comparable, high level of ER␤ cells coexpressing ER␣ in the PvPO, the BNST, and the MEApd when examining the colocalization of ER␤ mRNA and ER␣-ir. In contrast in the present study because the number of ER␤-ir cells is lower than the number of ER␤ mRNA cells in the brain regions observed, the levels of ER␣-containing cell coexpressing ER␤ are lower than those reported in the earlier study (18) . Nevertheless, these findings provide evidence that ER␣ and ER␤ have the opportunity to interact in vivo intracellularly in a small population of limbic and hypothalamic neurons. Furthermore, it suggests that in these brain regions, transcriptional regulation by E2 could occur via at least three classes of cells: cells containing ER␣, ER␤, or both. Because ER␤ expression decreased in the PvPO after E2 treatment, the number of ER␣ neurons containing ER␤ decreased significantly. This decrease in neurons coexpressing both ERs also results in an increase in the number of cells expressing only ER␣-ir. In contrast to the E2-induced decrease in ER␤ in the PvPO, in the MEApd ER␣ expression significantly decreased after E2 treatment, which induced an increase in the number of cells expressing ER␤ only. As previously mentioned, ER␣ and ER␤ isoforms have the ability to form heterodimers (10, 34) , which have different transcriptional activities than ER homodimers (11) . Together with the present data, this further suggests that differential regulation of ERs by E2 may lead to cells with different profiles of E responsiveness in a brain region-specific manner.
The neural distribution of PgRs in females and the increase in its expression by E2 in some brain regions have been described extensively using a variety of techniques (30, 31, 40) . In other immunocytochemical studies, a limited distribution of PgR-ir has been observed in the brain due to the sensitivity of the immunocytochemical procedure adjusted so that either only cells in which E2-induced PgR-ir were labeled (30) or only dark nuclear staining was observed (32) . Using a higher concentration of antibody than had been used previously, we detected PgR-ir in neurons of regions previously described as containing E2-induced PgR, such as in the PvPO, the preoptic area, the BNSTpr, the lateral ventromedial hypothalamus, the arcuate nucleus and the MEApd, as well as E2-independent PgR such as in the PVN and the cerebral cortex (31, (41) (42) (43) . The requirement of a higher concentration of antibody necessary to visualize PgR in the PVN and the cortex suggests a lower abundance of the receptor in these regions. Both isoforms of PgR (PgR-A and PgR-B) have been detected in the brain (41) . Although it has been suggested that the expression of one of the two PgR isoforms (PgR-B) has less dependence on E2 (41), the PgR antibody used here recognizes both PgR isoforms and does not allow us to discriminate the two. In accordance with previous reports (30) , E2 injection increased the expression of PgR-ir, as seen in the present study by an increase in optical intensity in the PvPO, BNSTpr, and MEApd, but no effect of E2 on PgR expression was detected in the PVN. This finding agrees with earlier ligand binding studies in which progesterone binding was seen throughout the brain, but E2 treatments increased PgR expression only in limited areas (44) .
Although the coexpression of PgR and ER␤ has been reported in cell lines and human tumor cells (12, 45) , we report here the in vivo coexpression of PgR-ir and ER␤-ir in neurons of the PvPO, the BNSTpr, the MEApd, and the PVN of female rat brains. Depending on the region and the hormonal status of the females, 20 -50% of the PgR-ir cells coexpressed ER␤-ir. Conversely in the PvPO and PVN, over 70% of the ER␤-ir cells coexpressed PgR-ir, whereas only about 45% did in the BNSTpr and the MEApd. It is well known that E2 induces the expression of PgR in ER␣-containing cells of the female brain (15, 46) . In the present study E2-induced PgR-ir was measured by an increase in the intensity of PgR-ir. It is important to note that ER␤-ir was found in cells containing E2-induced PgR-ir (EB-treated) as well as cells containing E2-indepen- dent PgR-ir (i.e. in oil-treated rats) in all regions tested. More specifically, about 30% of cells that showed an increased expression of PgR-ir coexpressed ER␤-ir. We did not test for the presence of ER␣ in these cells. However, as mentioned earlier, E2-induced PgR-ir is almost exclusively in ER␣-containing cells (15) , strongly supporting the idea that cells with E2-induced PgR and ER␤-ir may also contain ER␣.
In ER␣-gene disrupted (ER␣KO) mice, E2 treatment increased the expression of PgR mRNA in the PvPO (16) and of PgR-ir in the MEApd as well as in the arcuate nucleus and the lateral ventromedial hypothalamus (17) . Although our present data suggest the involvement of both ER␣ and ER␤ in the regulation of PgR expression, future studies using various steroid receptor gene-disrupted models will be needed to further examine whether the induction of PgR expression by E2 is mediated by ER␣ variants, ER␤, or both.
It has recently been shown that ER␤ plays a modest role, if any, in the regulation of female sexual behavior. Indeed, although sexual behavior is not impaired in ER␤ genedisrupted mice, the duration of sexual receptivity in females is extended compared with that in wild-type animals (47) . On the other hand, the brain regions in which ER␤-ir is present are known to be involved in gonadal hormone regulation of a variety of neuroendocrine systems. For example, the posterior medial BNST (level equivalent to the BNSTpr) is involved in the regulation of the CRH expression in the PVN (48), the expression of which is regulated by gonadal hormones. Likewise, in the supraoptic nucleus and PVN, ER␤ has been located in oxytocin-and vasopressin-containing cells (33) , which are involved in reproductive functions.
Our results demonstrated that ER␤ is present in cells containing other steroid receptors in brain regions that are of importance in females, and they suggest that ER␤ alone or in combination with ER␣ and/or PgR may participate in the hormonal regulation of a variety of neuroendocrine functions. Furthermore, our results suggest that E2 may play a crucial role in regulating amounts of ERs (␣ and ␤) and PgRs in cells in a brain-region specific manner, which may, in turn, induce differential expression of relevant genes.
